


KardiaMobile is making at-home ECG monitoring for AF easier and more accurate than ever.

Read the Medtech Innovation Briefing (NICE MIB232) to learn more about how our technology can support you and your patients.



We're proud to be recognised by NICE for the fast and precise ambulatory detection of atrial fibrillation in the recently published [Medtech Innovation Briefing \(NICE MIB232\)](#), which demonstrates how AliveCor's technology can support patients and health care professionals, and highlights our alignment to the NHS long term plan.



Our Technology

KardiaMobile is the most clinically-validated mobile ECG solution available worldwide.

KardiaMobile is an FDA-cleared, CE-marked, medical-grade personal ECG device. Our AI-driven technology can detect the most common arrhythmias—AF, bradycardia, and tachycardia—in just 30 seconds. Users receive instant analysis of their ECG right on their smartphone and can send to their clinician with the press of a button.



Our clinical enterprise solution, KardiaPro, connects with KardiaMobile and KardiaMobile 6L to enhance patient care and streamline ECG interpretation through remote patient monitoring.

Patient ECG data is transmitted automatically from the Kardia app to your practice's KardiaPro portal.

Highlights from the NICE MIB232 report:



The published evidence from 11 studies, across 1,218 adult patients, demonstrates that KardiaMobile can detect **more** cardiac arrhythmias, but can do so **faster than standard care**.



The brief showcases KardiaMobile's diagnostic accuracy for detection of cardiac arrhythmias with sensitivity ranging between 77.0% and 96.6% and specificity ranging between 76.0% and 99.1%.



KardiaMobile is suitable for patients to use with suspected paroxysmal AF, which might not be detected using a standard 12-lead ECG if the person is not in arrhythmia at the time of recording.



The convenience of an at-home medical-grade ECG that can be taken at any time of the day increases the diagnostic yield of an arrhythmic episode being detected and recorded.

Recognition by Clinical Experts

"All experts stated that this technology had the potential to change standard care in some way (earlier diagnosis, quicker intervention, fewer hospital visits and referrals, fewer strokes) improving both patient outcomes and patient satisfaction."



Recognition by Patient Groups

"Having KardiaMobile readily available across the NHS and in pharmacies would: make sure patients can capture their irregular heart rhythms; allow collection of the evidence to show their doctors AF; protect against AF-related stroke with anticoagulation therapy; help patients to access appropriate treatments to manage the symptoms and correct arrhythmia."

"Patient subgroups who could particularly benefit from the technology include symptomatic patients who have yet to be diagnosed, and those who have paroxysmal AF (which is hard to detect on a standard 12-lead electrocardiogram or Holter monitor)."

To read the full report, please visit our resource hub at livecor.co.uk/resource-hub.

Email sean.warren@livecor.co.uk for more information.